Relmada Therapeutics (RLMD) Expected to Announce Earnings on Tuesday

Relmada Therapeutics (NASDAQ:RLMD) is anticipated to post its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Relmada Therapeutics to post earnings of ($0.60) per share for the quarter.

Relmada Therapeutics Price Performance

Shares of RLMD stock opened at $0.29 on Friday. Relmada Therapeutics has a 1 year low of $0.24 and a 1 year high of $5.84. The stock’s 50 day simple moving average is $0.34 and its two-hundred day simple moving average is $1.75. The company has a market cap of $8.83 million, a PE ratio of -0.10 and a beta of 0.65.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on RLMD. Mizuho reiterated a “neutral” rating and issued a $1.00 price target (down from $23.00) on shares of Relmada Therapeutics in a report on Thursday, December 5th. Leerink Partners reiterated a “market perform” rating and issued a $1.00 price target (down from $10.00) on shares of Relmada Therapeutics in a report on Wednesday, December 4th. Finally, Leerink Partnrs downgraded Relmada Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 4th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Relmada Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $4.25.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.